{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:45:00Z","timestamp":1795113900474,"version":"4.10.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloid beta protein (A\u03b2) is a treatment target in Alzheimer\u2019s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-responsive element in APP mRNA and decreases translation of APP and A\u03b2. To augment human data for Posiphen, we evaluated safety, tolerability and pharmacokinetic and pharmacodynamic (PD) effects on A\u03b2 metabolism using Stable Isotope Labeling Kinetic (SILK) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Double-blind phase 1b randomized ascending dose clinical trial, at five sites, under an IRB-approved protocol. Participants with mild cognitive impairment or mild AD (Early AD) confirmed by low CSF A\u03b242\/40 were randomized (within each dose arm) to Posiphen or placebo. Pretreatment assessment included lumbar puncture for CSF. Participants took Posiphen or placebo for 21\u201323 days, then underwent CSF catheter placement, intravenous infusion of\n                      <jats:sup>13<\/jats:sup>\n                      C\n                      <jats:sub>6<\/jats:sub>\n                      -leucine, and CSF sampling for 36\u00a0h. Safety and tolerability were assessed through participant reports, EKG and laboratory tests. CSF SILK analysis measured A\u03b240, 38 and 42 with immunoprecipitation-mass spectrometry. Baseline and day 21 CSF APP, A\u03b2 and other biomarkers were measured with immunoassays. The Mini-Mental State Exam and ADAS-cog12 were given at baseline and day 21.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From June 2017 to December 2021, 19 participants were enrolled, randomized within dose cohorts (5 active: 3 placebo) of 60\u00a0mg once\/day and 60\u00a0mg twice\/day; 1 participant was enrolled and completed 60\u00a0mg three times\/day. 10 active drug and 5 placebo participants completed all study procedures. Posiphen was safe and well-tolerated. 8 participants had headaches related to CSF catheterization; 5 needed blood patches. Prespecified SILK analyses of Fractional Synthesis Rate (FSR) for CSF A\u03b240 showed no significant overall or dose-dependent effects of Posiphen vs. placebo. Comprehensive multiparameter modeling of APP kinetics supported dose-dependent lowering of APP production by Posiphen. Cognitive measures and CSF biomarkers did not change significantly from baseline to 21 days in Posiphen vs. placebo groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Posiphen was safe and well-tolerated in Early AD. A multicenter SILK study was feasible. Findings are limited by small sample size but provide additional supportive safety and PK data. Comprehensive modeling of biomarker dynamics using SILK data may reveal subtle drug effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT02925650 on clinicaltrials.gov (registered on 10-24-2016).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01490-z","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T02:02:08Z","timestamp":1720144928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer\u2019s Disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Douglas","family":"Galasko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Farlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan P.","family":"Lucey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Elbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Momper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Pa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahan","family":"Aslanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maccecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"5441","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.286.5441.916","volume":"286","author":"C Haass","year":"1999","unstructured":"Haass C, De Strooper B. The presenilins in Alzheimer\u2019s disease\u2013proteolysis holds the key. Science. 1999;286(5441):916\u20139. https:\/\/doi.org\/10.1126\/science.286.5441.916.","journal-title":"Science"},{"issue":"2","key":"1490_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/01.wnl.0000303973.71803.81","volume":"71","author":"JM Ringman","year":"2008","unstructured":"Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85\u201392. https:\/\/doi.org\/10.1212\/01.wnl.0000303973.71803.81.","journal-title":"Neurology"},{"issue":"5","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/s0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer\u2019s disease-linked presenilin 1 variants elevate Abeta1-42\/1\u201340 ratio in vitro and in vivo. Neuron. 1996;17(5):1005\u201313. https:\/\/doi.org\/10.1016\/s0896-6273(00)80230-5.","journal-title":"Neuron"},{"issue":"8","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2(8):864\u201370. https:\/\/doi.org\/10.1038\/nm0896-864.","journal-title":"Nat Med"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fneur.2015.00142","volume":"6","author":"SE Schindler","year":"2015","unstructured":"Schindler SE, Fagan AM. Autosomal Dominant Alzheimer Disease: a Unique Resource to study CSF biomarker changes in preclinical AD. Front Neurol. 2015;6:142. https:\/\/doi.org\/10.3389\/fneur.2015.00142.","journal-title":"Front Neurol"},{"issue":"Pt 11","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/brain\/awl203","volume":"129","author":"K Sleegers","year":"2006","unstructured":"Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer\u2019s dementia with cerebral amyloid angiopathy. Brain. 2006;129(Pt 11):2977\u201383. https:\/\/doi.org\/10.1093\/brain\/awl203.","journal-title":"Brain"},{"issue":"1","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24\u20136. https:\/\/doi.org\/10.1038\/ng1718.","journal-title":"Nat Genet"},{"issue":"11","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(11):930\u201342. https:\/\/doi.org\/10.1016\/S1474-4422(21)00245-3.","journal-title":"Lancet Neurol"},{"issue":"7409","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96\u20139. https:\/\/doi.org\/10.1038\/nature11283.","journal-title":"Nature"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mcn.2019.02.003","volume":"95","author":"I Martinsson","year":"2019","unstructured":"Martinsson I, Capetillo-Zarate E, Faideau M, et al. APP depletion alters selective pre- and post-synaptic proteins. Mol Cell Neurosci. 2019;95:86\u201395. https:\/\/doi.org\/10.1016\/j.mcn.2019.02.003.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0306-4522(98)00410-2","volume":"90","author":"GR Dawson","year":"1999","unstructured":"Dawson GR, Seabrook GR, Zheng H, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90(1):1\u201313. https:\/\/doi.org\/10.1016\/s0306-4522(98)00410-2.","journal-title":"Neuroscience"},{"issue":"4","key":"1490_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0092-8674(95)90073-x","volume":"81","author":"H Zheng","year":"1995","unstructured":"Zheng H, Jiang M, Trumbauer ME, et al. beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81(4):525\u201331. https:\/\/doi.org\/10.1016\/0092-8674(95)90073-x.","journal-title":"Cell"},{"issue":"41","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"31217","DOI":"10.1074\/jbc.M110.149161","volume":"285","author":"HH Cho","year":"2010","unstructured":"Cho HH, Cahill CM, Vanderburg CR, et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem. 2010;285(41):31217\u201332. https:\/\/doi.org\/10.1074\/jbc.M110.149161.","journal-title":"J Biol Chem"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"142372","DOI":"10.1155\/2012\/142372","volume":"2012","author":"S Mikkilineni","year":"2012","unstructured":"Mikkilineni S, Cantuti-Castelvetri I, Cahill CM, Balliedier A, Greig NH, Rogers JT. The anticholinesterase phenserine and its enantiomer posiphen as 5\u2019untranslated-region-directed translation blockers of the Parkinson\u2019s alpha synuclein expression. Parkinsons Dis. 2012;2012:142372. https:\/\/doi.org\/10.1155\/2012\/142372.","journal-title":"Parkinsons Dis"},{"issue":"13","key":"1490_CR15","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1073\/pnas.131152998","volume":"98","author":"KT Shaw","year":"2001","unstructured":"Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A. 2001;98(13):7605\u201310. https:\/\/doi.org\/10.1073\/pnas.131152998.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/acsptsci.1c00200","volume":"5","author":"S Batool","year":"2022","unstructured":"Batool S, Furqan T, Hasan Mahmood MS, Tweedie D, Kamal MA, Greig NH. In Silico and Ex vivo analyses of the inhibitory action of the Alzheimer Drug Posiphen and primary metabolites with human acetyl- and butyrylcholinesterase enzymes. ACS Pharmacol Transl Sci. 2022;5(2):70\u20139. https:\/\/doi.org\/10.1021\/acsptsci.1c00200.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"104528","DOI":"10.1016\/j.nbd.2019.104528","volume":"130","author":"D Lecca","year":"2019","unstructured":"Lecca D, Bader M, Tweedie D, et al. (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer\u2019s disease challenged mice. Neurobiol Dis. 2019;130:104528. https:\/\/doi.org\/10.1016\/j.nbd.2019.104528.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/alz.12185","volume":"17","author":"XQ Chen","year":"2021","unstructured":"Chen XQ, Salehi A, Pearn ML, et al. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement. 2021;17(2):271\u201392. https:\/\/doi.org\/10.1002\/alz.12185.","journal-title":"Alzheimers Dement"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1034\/j.1600-0404.2000.00311.x","volume":"176","author":"NH Greig","year":"2000","unstructured":"Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl. 2000;176:74\u201384. https:\/\/doi.org\/10.1034\/j.1600-0404.2000.00311.x.","journal-title":"Acta Neurol Scand Suppl"},{"issue":"9","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","volume":"83","author":"ML Maccecchini","year":"2012","unstructured":"Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-\u03b2 peptide and \u03c4 levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry. 2012;83(9):894\u2013902. https:\/\/doi.org\/10.1136\/jnnp-2012-302589.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1490_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14283\/jpad.2022.84","volume":"10","author":"C Fang","year":"2023","unstructured":"Fang C, Hernandez P, Liow K, et al. Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer\u2019s and Parkinson\u2019s patients. J Prev Alzheimers Dis. 2023;10(1):25\u201333. https:\/\/doi.org\/10.14283\/jpad.2022.84.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"1490_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41582-019-0222-0","volume":"15","author":"RW Paterson","year":"2019","unstructured":"Paterson RW, Gabelle A, Lucey BP, et al. SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. Nat Rev Neurol. 2019;15(7):419\u201327. https:\/\/doi.org\/10.1038\/s41582-019-0222-0.","journal-title":"Nat Rev Neurol"},{"issue":"6012","key":"1490_CR23","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease. Science. 2010;330(6012):1774. https:\/\/doi.org\/10.1126\/science.1197623.","journal-title":"Science"},{"issue":"1","key":"1490_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.21623","volume":"66","author":"RJ Bateman","year":"2009","unstructured":"Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66(1):48\u201354. https:\/\/doi.org\/10.1002\/ana.21623.","journal-title":"Ann Neurol"},{"issue":"1","key":"1490_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ana.25117","volume":"83","author":"BP Lucey","year":"2018","unstructured":"Lucey BP, Hicks TJ, McLeland JS, et al. Effect of sleep on overnight cerebrospinal fluid amyloid \u03b2 kinetics. Ann Neurol. 2018;83(1):197\u2013204. https:\/\/doi.org\/10.1002\/ana.25117.","journal-title":"Ann Neurol"},{"issue":"24","key":"1490_CR26","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1523\/JNEUROSCI.0540-14.2014","volume":"34","author":"JA Dobrowolska","year":"2014","unstructured":"Dobrowolska JA, Michener MS, Wu G, et al. CNS amyloid-\u03b2, soluble APP-\u03b1 and -\u03b2 kinetics during BACE inhibition. J Neurosci. 2014;34(24):8336\u201346. https:\/\/doi.org\/10.1523\/JNEUROSCI.0540-14.2014.","journal-title":"J Neurosci"},{"issue":"3","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"e89998","DOI":"10.1371\/journal.pone.0089998","volume":"9","author":"JA Dobrowolska","year":"2014","unstructured":"Dobrowolska JA, Kasten T, Huang Y, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS ONE. 2014;9(3):e89998. https:\/\/doi.org\/10.1371\/journal.pone.0089998.","journal-title":"PLoS ONE"},{"key":"1490_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.taap.2017.03.014","volume":"323","author":"HA Schoenfeld","year":"2017","unstructured":"Schoenfeld HA, West T, Verghese PB, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril\/valsartan, on central nervous system amyloid-\u03b2 concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharmacol. 2017;323:53\u201365. https:\/\/doi.org\/10.1016\/j.taap.2017.03.014.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"1490_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1490_CR30","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a.","journal-title":"Neurology"},{"issue":"3","key":"1490_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"11","key":"1490_CR32","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141(11):1356\u201364. https:\/\/doi.org\/10.1176\/ajp.141.11.1356.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1490_CR33","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314. https:\/\/doi.org\/10.1212\/wnl.44.12.2308.","journal-title":"Neurology"},{"key":"1490_CR34","doi-asserted-by":"publisher","first-page":"106140","DOI":"10.1016\/j.nbd.2023.106140","volume":"182","author":"R Wittrahm","year":"2023","unstructured":"Wittrahm R, Takalo M, Kuulasmaa T, et al. Protective Alzheimer\u2019s disease-associated APP A673T variant predominantly decreases sAPP\u03b2 levels in cerebrospinal fluid and 2D\/3D cell culture models. Neurobiol Dis. 2023;182:106140. https:\/\/doi.org\/10.1016\/j.nbd.2023.106140.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1490_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s42003-022-03037-0","volume":"5","author":"DL Elbert","year":"2022","unstructured":"Elbert DL, Patterson BW, Lucey BP, Benzinger TLS, Bateman RJ. Importance of CSF-based A\u03b2 clearance with age in humans increases with declining efficacy of blood-brain barrier\/proteolytic pathways. Commun Biol. 2022;5(1):98. https:\/\/doi.org\/10.1038\/s42003-022-03037-0.","journal-title":"Commun Biol"},{"issue":"6","key":"1490_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913\u201322. https:\/\/doi.org\/10.1016\/j.neuron.2005.10.028.","journal-title":"Neuron"},{"key":"1490_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trci.2017.12.001","volume":"4","author":"AF Teich","year":"2018","unstructured":"Teich AF, Sharma E, Barnwell E, et al. Translational inhibition of APP by Posiphen: efficacy, pharmacodynamics, and pharmacokinetics in the APP\/PS1 mouse. Alzheimers Dement (N Y). 2018;4:37\u201345. https:\/\/doi.org\/10.1016\/j.trci.2017.12.001.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"236","key":"1490_CR38","doi-asserted-by":"publisher","first-page":"236re4","DOI":"10.1126\/scitranslmed.3008169","volume":"6","author":"YI Sheline","year":"2014","unstructured":"Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4. https:\/\/doi.org\/10.1126\/scitranslmed.3008169.","journal-title":"Sci Transl Med"},{"key":"1490_CR39","doi-asserted-by":"publisher","first-page":"883256","DOI":"10.3389\/fnagi.2022.883256","volume":"14","author":"Y Bouter","year":"2022","unstructured":"Bouter Y, Bouter C. Selective serotonin reuptake inhibitor-treatment does not show Beneficial effects on cognition or amyloid burden in cognitively impaired and cognitively normal subjects. Front Aging Neurosci. 2022;14:883256. https:\/\/doi.org\/10.3389\/fnagi.2022.883256.","journal-title":"Front Aging Neurosci"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01490-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T02:05:48Z","timestamp":1720145148000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01490-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.20.24304638","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"the study was approved by the UCSD Human Research Protection Program, operating under Federalwide Assurance number, FWA00004495. All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MM is an employee of Annovis Bio, TW is an employee of C2N Diagnostics, RB is a cofounder of C2N Diagnostics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}